mupirocin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
aminoacyl-tRNA synthetase inhibitors 1857 12650-69-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • mupirocin
  • mupricin
  • pseudomonic acid
  • turixin
  • mupirocin calcium
  • bactroban
  • BRL 4910A
A topically used antibiotic from a strain of Pseudomonas fluorescens. It has shown excellent activity against gram-positive staphylococci and streptococci. The antibiotic is used primarily for the treatment of primary and secondary skin disorders, nasal infections, and wound healing.
  • Molecular weight: 500.63
  • Formula: C26H44O9
  • CLOGP: 1.54
  • LIPINSKI: 1
  • HAC: 9
  • HDO: 4
  • TPSA: 146.05
  • ALOGS: -4.28
  • ROTB: 17
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,JAK3,MAP2K6,MAPK10,MAPK7,NTRK2,PDK1,PDK2,PDK4,PRKDC,SYK,TEK,TGFBR1,ZAP70 26
kinase-selectivity-class AXL,EIF2AK3,GRK2,MAP2K6 4
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
Dec. 31, 1987 FDA GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Macular degeneration 1211.93 15.01 419 20613 37551 90569864
Chronic sinusitis 422.15 15.01 171 20861 23631 90583784
Vaginal flatulence 362.43 15.01 129 20903 12509 90594906
Paraesthesia oral 359.48 15.01 166 20866 31493 90575922
Female genital tract fistula 343.25 15.01 136 20896 17732 90589683
Proctitis 338.72 15.01 129 20903 15130 90592285
Radiculopathy 335.18 15.01 135 20897 18370 90589045
Vaginal discharge 311.65 15.01 130 20902 19334 90588081
Procedural pain 299.86 15.01 149 20883 33211 90574204
Oral candidiasis 259.75 15.01 138 20894 35317 90572098
Colitis 215.98 15.01 157 20875 69785 90537630
Colitis ulcerative 210.85 15.01 146 20886 60120 90547295
Therapeutic product effect incomplete 204.32 15.01 238 20794 193658 90413757
Frequent bowel movements 187.67 15.01 133 20899 56802 90550613
Rectal haemorrhage 173.84 15.01 148 20884 82596 90524819
Haematochezia 172.27 15.01 138 20894 70775 90536640
Erythema 141.91 15.01 217 20815 229029 90378386
Dermatitis atopic 132.52 15.01 77 20955 23395 90584020
Drug ineffective 131.24 15.01 649 20383 1383649 89223766
Weight decreased 129.13 15.01 277 20755 379633 90227782
Dyspepsia 109.31 15.01 178 20854 197982 90409433
Dry skin 85.81 15.01 104 20928 87969 90519446
Constipation 81.20 15.01 192 20840 280203 90327212
Skin exfoliation 72.43 15.01 84 20948 67829 90539586
Anaemia 71.02 15.01 211 20821 352591 90254824
Systemic lupus erythematosus 55.02 15.01 9 21023 361887 90245528
Skin weeping 52.65 15.01 21 21011 2779 90604636
Toxicity to various agents 51.63 15.01 4 21028 287842 90319573
General physical health deterioration 47.41 15.01 12 21020 355103 90252312
Pyrexia 44.84 15.01 284 20748 660201 89947214
Hepatic enzyme increased 44.79 15.01 14 21018 360722 90246693
Abdominal pain 44.69 15.01 196 20836 395525 90211890
Malaise 42.92 15.01 257 20775 585729 90021686
Eczema 41.34 15.01 56 20976 52814 90554601
Therapeutic product effect decreased 39.80 15.01 8 21024 277563 90329852
Skin fissures 39.18 15.01 35 20997 20774 90586641
Headache 39.14 15.01 337 20695 862409 89745006
Hyperchlorhydria 38.04 15.01 15 21017 1926 90605489
Staphylococcal infection 37.40 15.01 51 20981 48388 90559027
Nasal vestibulitis 37.05 15.01 8 21024 116 90607299
Nausea 35.42 15.01 403 20629 1109913 89497502
Lower respiratory tract infection 34.36 15.01 8 21024 250651 90356764
Contraindicated product administered 33.81 15.01 16 21016 320123 90287292
Maternal exposure during pregnancy 33.65 15.01 21 21011 360042 90247373
Arthropathy 32.02 15.01 23 21009 366219 90241196
Folliculitis 31.22 15.01 5 21027 204348 90403067
Folate deficiency 30.99 15.01 15 21017 3150 90604265
Swelling 30.91 15.01 31 21001 419027 90188388
Skin warm 30.13 15.01 20 21012 7667 90599748
Confusional state 29.14 15.01 28 21004 386177 90221238
Purpura senile 28.44 15.01 9 21023 606 90606809
Exposure during pregnancy 28.27 15.01 10 21022 238400 90369015
Drug intolerance 27.76 15.01 38 20994 447553 90159862
Humidity intolerance 27.36 15.01 8 21024 412 90607003
Skin haemorrhage 27.18 15.01 29 21003 21351 90586064
Hypersensitivity 26.82 15.01 40 20992 454637 90152778
Fibromyalgia 25.59 15.01 8 21024 206261 90401154
Pain 25.41 15.01 347 20685 995994 89611421
Tarsal tunnel syndrome 24.86 15.01 8 21024 569 90606846
Product dose omission issue 24.62 15.01 133 20899 291554 90315861
Mobility decreased 22.90 15.01 15 21017 250719 90356696
Appetite disorder 22.63 15.01 18 21014 9115 90598300
Skin lesion 22.53 15.01 35 20997 37330 90570085
Autoimmune pericarditis 21.99 15.01 5 21027 93 90607322
Type 2 diabetes mellitus 21.69 15.01 10 21022 203234 90404181
Pruritus 21.63 15.01 206 20826 541319 90066096
Ill-defined disorder 21.50 15.01 8 21024 184883 90422532
Impaired healing 21.40 15.01 14 21018 234185 90373230
Product use in unapproved indication 21.15 15.01 142 20890 336094 90271321
Irritable bowel syndrome 20.94 15.01 11 21021 207437 90399978
Treatment failure 20.71 15.01 24 21008 303904 90303511
Bursitis 20.61 15.01 3 21029 131651 90475764
Injection site pain 20.29 15.01 87 20945 173612 90433803
Sleep disorder due to general medical condition, insomnia type 19.99 15.01 3 21029 128691 90478724
Dermatitis 19.63 15.01 25 21007 22195 90585220
Cellulitis 19.63 15.01 56 20976 91281 90516134
Staphylococcal scalded skin syndrome 19.61 15.01 5 21027 153 90607262
Joint range of motion decreased 19.24 15.01 4 21028 135639 90471776
Off label use 19.08 15.01 360 20672 1101892 89505523
Resorption bone increased 19.02 15.01 8 21024 1211 90606204
Joint swelling 18.99 15.01 57 20975 503243 90104172
Infusion related reaction 18.90 15.01 163 20869 416617 90190798
Odynophagia 18.60 15.01 16 21016 9027 90598388
Wound 18.49 15.01 26 21006 302954 90304461
Rash pruritic 18.25 15.01 51 20981 82163 90525252
Therapeutic product effect delayed 18.08 15.01 11 21021 3630 90603785
Sleep disorder due to a general medical condition 17.93 15.01 35 20997 44703 90562712
Injury 17.75 15.01 12 21020 197337 90410078
Skin disorder 17.58 15.01 31 21001 36675 90570740
Weight increased 17.50 15.01 45 20987 417882 90189533
Spinal synovial cyst 17.46 15.01 4 21028 77 90607338
Musculoskeletal pain 17.40 15.01 9 21023 171242 90436173
Illness 17.37 15.01 50 20982 81919 90525496
Stomatitis 17.34 15.01 23 21009 274675 90332740
Injection site swelling 17.29 15.01 41 20991 59798 90547617
Skin infection 17.22 15.01 21 21011 17843 90589572
Intentional product use issue 17.20 15.01 15 21017 216877 90390538
Vestibular disorder 17.18 15.01 8 21024 1541 90605874
Dysphoria 17.14 15.01 13 21019 6141 90601274
Hypertension 17.13 15.01 52 20980 457480 90149935
Linear IgA disease 17.06 15.01 9 21023 2265 90605150
Blood cholesterol increased 16.97 15.01 14 21018 207998 90399417
Skin irritation 16.50 15.01 18 21014 13585 90593830
Bronchial oedema 16.43 15.01 4 21028 101 90607314
Seborrhoeic dermatitis 16.38 15.01 8 21024 1712 90605703
Discomfort 16.29 15.01 24 21008 274311 90333104
Alopecia 15.98 15.01 60 20972 495011 90112404
Musculoskeletal stiffness 15.68 15.01 28 21004 296504 90310911
Pain of skin 15.66 15.01 19 21013 16063 90591352
Cough 15.53 15.01 142 20890 368820 90238595
Pustule 15.06 15.01 9 21023 2874 90604541

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dermatitis atopic 154.66 15.92 66 8275 12338 42600656
Pruritus 72.30 15.92 131 8210 188640 42424354
Nasal vestibulitis 57.65 15.92 9 8332 19 42612975
Dry skin 47.91 15.92 53 8288 48285 42564709
Product use in unapproved indication 44.58 15.92 106 8235 184350 42428644
Skin exfoliation 41.93 15.92 46 8295 41507 42571487
Skin fissures 38.87 15.92 24 8317 9652 42603342
Staphylococcal infection 38.55 15.92 42 8299 37601 42575393
Food aversion 35.97 15.92 10 8331 511 42612483
Injection site pain 34.23 15.92 49 8292 57749 42555245
Rash 33.96 15.92 125 8216 276829 42336165
Seborrhoeic keratosis 28.01 15.92 11 8330 1660 42611334
Eczema 26.47 15.92 33 8308 34053 42578941
Toxic epidermal necrolysis 25.92 15.92 29 8312 26721 42586273
Burkholderia test positive 25.23 15.92 9 8332 1041 42611953
Pain of skin 24.97 15.92 17 8324 8063 42604931
Cheilitis 23.29 15.92 11 8330 2597 42610397
Sleep disorder due to a general medical condition 22.42 15.92 22 8319 17431 42595563
Hordeolum 21.53 15.92 9 8332 1593 42611401
Cellulitis 21.30 15.92 41 8300 61544 42551450
Dermatitis 21.19 15.92 18 8323 11857 42601137
Skin discolouration 20.84 15.92 23 8318 20867 42592127
Skin discomfort 20.33 15.92 7 8334 729 42612265
Product dose omission issue 19.98 15.92 71 8270 154294 42458700
Toxicity to various agents 19.91 15.92 10 8331 229126 42383868
Lentigo 19.48 15.92 7 8334 827 42612167
Scratch 18.51 15.92 12 8329 5249 42607745
Skin weeping 18.34 15.92 8 8333 1571 42611423
Cutaneous T-cell lymphoma 16.54 15.92 8 8333 1990 42611004
Urine phosphorus increased 16.20 15.92 4 8337 128 42612866
Melanocytic naevus 16.18 15.92 9 8332 2983 42610011
Hypophagia 16.16 15.92 23 8318 26933 42586061

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Macular degeneration 460.28 13.94 175 24254 21484 110543386
Chronic sinusitis 407.85 13.94 167 24262 24917 110539953
Vaginal flatulence 369.76 13.94 128 24301 12016 110552854
Female genital tract fistula 356.46 13.94 135 24294 16384 110548486
Paraesthesia oral 351.24 13.94 164 24265 33507 110531363
Radiculopathy 339.29 13.94 136 24293 19200 110545670
Proctitis 331.84 13.94 129 24300 16798 110548072
Vaginal discharge 324.79 13.94 129 24300 17779 110547091
Procedural pain 306.59 13.94 152 24277 35413 110529457
Oral candidiasis 235.99 13.94 138 24291 44622 110520248
Dermatitis atopic 193.32 13.94 100 24329 25441 110539429
Colitis ulcerative 184.62 13.94 146 24283 77217 110487653
Colitis 180.06 13.94 162 24267 102161 110462709
Frequent bowel movements 170.93 13.94 135 24294 71255 110493615
Rectal haemorrhage 145.75 13.94 155 24274 119678 110445192
Therapeutic product effect incomplete 142.26 13.94 209 24220 223596 110341274
Erythema 131.66 13.94 233 24196 291214 110273656
Haematochezia 129.25 13.94 143 24286 115381 110449489
Weight decreased 128.08 13.94 304 24125 467753 110097117
Dyspepsia 117.96 13.94 176 24253 190789 110374081
Dry skin 94.98 13.94 118 24311 107535 110457335
Constipation 71.68 13.94 207 24222 357579 110207291
Toxicity to various agents 63.97 13.94 14 24415 480541 110084329
Anaemia 56.63 13.94 255 24174 546831 110018039
Skin exfoliation 55.80 13.94 82 24347 87569 110477301
Abdominal pain 50.77 13.94 236 24193 512753 110052117
Pruritus 50.01 13.94 257 24172 581303 109983567
Skin fissures 49.56 13.94 42 24387 24416 110540454
Eczema 46.55 13.94 68 24361 72225 110492645
Headache 41.20 13.94 334 24095 882043 109682827
Pain 38.56 13.94 350 24079 954605 109610265
Hepatic enzyme increased 37.64 13.94 12 24417 320880 110243990
General physical health deterioration 37.30 13.94 24 24405 425271 110139599
Staphylococcal infection 36.89 13.94 60 24369 69884 110494986
Systemic lupus erythematosus 36.81 13.94 6 24423 254332 110310538
Pyrexia 36.65 13.94 330 24099 897935 109666935
Malaise 35.59 13.94 262 24167 671557 109893313
Skin weeping 35.26 13.94 17 24412 3718 110561152
Hyperchlorhydria 33.73 13.94 14 24415 2155 110562715
Product dose omission issue 33.23 13.94 150 24279 321632 110243238
Nausea 32.67 13.94 416 24013 1235274 109329596
Lower respiratory tract infection 32.48 13.94 7 24422 243099 110321771
Injection site pain 31.84 13.94 99 24330 177823 110387047
Cellulitis 31.30 13.94 79 24350 125937 110438933
Drug interaction 30.98 13.94 39 24390 500144 110064726
Food aversion 30.26 13.94 12 24417 1643 110563227
Skin haemorrhage 28.19 13.94 31 24398 24796 110540074
Infusion related reaction 27.69 13.94 161 24268 381001 110183869
Confusional state 27.53 13.94 38 24391 468642 110096228
Fibromyalgia 27.18 13.94 3 24426 170906 110393964
Therapeutic product effect decreased 27.15 13.94 10 24419 244306 110320564
Folate deficiency 26.90 13.94 15 24414 4423 110560447
Humidity intolerance 26.37 13.94 8 24421 492 110564378
Tarsal tunnel syndrome 25.64 13.94 8 24421 541 110564329
Injection site swelling 24.79 13.94 47 24382 61743 110503127
Purpura senile 24.74 13.94 8 24421 607 110564263
Pain of skin 24.48 13.94 26 24403 20003 110544867
Body temperature abnormal 23.02 13.94 12 24417 3097 110561773
Autoimmune pericarditis 21.70 13.94 5 24424 104 110564766
Sleep disorder due to a general medical condition 21.35 13.94 40 24389 52072 110512798
Skin warm 21.20 13.94 17 24412 9153 110555717
Resorption bone increased 20.86 13.94 9 24420 1525 110563345
Neurodermatitis 20.81 13.94 11 24418 2921 110561949
Arthropathy 20.44 13.94 20 24409 287502 110277368
Contraindicated product administered 20.43 13.94 15 24414 248252 110316618
Skin infection 20.36 13.94 25 24404 22484 110542386
Scratch 19.80 13.94 19 24410 12960 110551910
Liver disorder 19.19 13.94 4 24425 142239 110422631
Intentional product use issue 19.11 13.94 16 24413 247890 110316980
Dermatitis 19.11 13.94 27 24402 27810 110537060
Treatment failure 18.89 13.94 20 24409 277214 110287656
Illness 18.84 13.94 50 24379 82121 110482749
Off label use 18.74 13.94 448 23981 1499737 109065133
Folliculitis 18.39 13.94 7 24422 167646 110397224
Ear pain 18.35 13.94 38 24391 53188 110511682
Drug intolerance 18.33 13.94 39 24390 406473 110158397
Appetite disorder 18.22 13.94 16 24413 9753 110555117
Product use in unapproved indication 17.48 13.94 163 24266 447214 110117656
Intentional overdose 17.32 13.94 4 24425 132497 110432373
Dysphoria 17.21 13.94 13 24416 6415 110558455
Bronchial oedema 17.02 13.94 4 24425 91 110564779
Skin discolouration 16.89 13.94 35 24394 49011 110515859
Dermatitis contact 16.85 13.94 18 24411 13935 110550935
Bursitis 16.83 13.94 4 24425 129914 110434956
Maternal exposure during pregnancy 16.69 13.94 19 24410 254864 110310006
Skin disorder 16.42 13.94 32 24397 42881 110521989
Hypersensitivity 16.40 13.94 41 24388 403957 110160913
Swelling 16.39 13.94 33 24396 351008 110213862
Mobility decreased 16.32 13.94 17 24412 237405 110327465
Hypertension 16.22 13.94 58 24371 510026 110054844
Surgery 16.06 13.94 31 24398 41252 110523618
Dry eye 16.01 13.94 37 24392 55756 110509114
Exposure via skin contact 15.95 13.94 17 24412 13130 110551740
Liver injury 15.34 13.94 7 24422 150406 110414464
Exposure during pregnancy 15.28 13.94 9 24420 167415 110397455
Sinus operation 15.17 13.94 9 24420 2982 110561888
Odynophagia 14.97 13.94 17 24412 14084 110550786
Irritable bowel syndrome 14.75 13.94 9 24420 164206 110400664
Overdose 14.70 13.94 18 24411 233776 110331094
Injection site erythema 14.67 13.94 50 24379 94126 110470744
Urine phosphorus increased 14.64 13.94 4 24425 169 110564701
Coma 14.55 13.94 4 24425 117865 110447005
Steroid withdrawal syndrome 14.36 13.94 6 24423 939 110563931
COVID-19 14.34 13.94 98 24331 244962 110319908
Linear IgA disease 14.31 13.94 10 24419 4379 110560491
Delirium 14.22 13.94 6 24423 135019 110429851
Sleep disorder due to general medical condition, insomnia type 14.19 13.94 3 24426 105640 110459230
Cutaneous T-cell lymphoma 14.14 13.94 9 24420 3375 110561495
Therapeutic product effect delayed 14.12 13.94 10 24419 4469 110560401

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC D06AX09 DERMATOLOGICALS
ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE
ANTIBIOTICS FOR TOPICAL USE
Other antibiotics for topical use
ATC R01AX06 RESPIRATORY SYSTEM
NASAL PREPARATIONS
DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
Other nasal preparations
FDA EPC N0000175515 RNA Synthetase Inhibitor Antibacterial
FDA MoA N0000175516 RNA Synthetase Inhibitors
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D011500 Protein Synthesis Inhibitors
CHEBI has role CHEBI:36047 antibacterial drug
CHEBI has role CHEBI:48001 protein synthesis inhibitor
CHEBI has role CHEBI:76969 bacterial metabolite
CHEBI has role CHEBI:33282 antibacterial agent
CHEBI has role CHEBI:35441 antiinfective agent
CHEBI has role CHEBI:73336 vulnerary

Related Drugs by ATC class:

D06AX Other antibiotics for topical use 12 drugs
amikacinbacitracinchloramphenicolfusidic acidgentamicinneomycinozenoxacinretapamulinrifamycinrifaximintyrothricinvirginiamycin
R01AX Other nasal preparations 6 drugs
framycetinhexamidinehyaluronic acidipratropiumretinolritiometan

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Impetigo indication 48277006 DOID:8504
Staph Aureus Traumatic Skin Lesion Infection indication
Methicillin-Resistant Staphylococcus Aureus Nasal Colonization indication
Traumatic Skin Lesion Streptococcus Pyogenes Infection indication
Folliculitis off-label use 13600006 DOID:4409
Atopic dermatitis off-label use 24079001 DOID:3310
Eczema off-label use 43116000
Epidermolysis bullosa off-label use 61003004 DOID:2730
Ecthyma off-label use 85791004
Furunculosis off-label use 112650006
Minor Bacterial Skin Infections off-label use
Skin irritation contraindication 367466007




🐶 Veterinary Drug Use

SpeciesUseRelation
Dogs Bacterial infections of the skin caused by strains of Staphylococcus aureus Indication
Dogs Bacterial infections of the skin caused by Staphylococcus intermedius Indication

🐶 Veterinary products

ProductApplicantIngredients
Bactoderm Ointment Zoetis Inc. 1
Muricin Fougera Pharmaceuticals Inc. 1
Mupirocin Ointment USP, 2% Taro Pharmaceuticals U.S.A. Inc. 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.76 acidic
pKa2 12.42 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Isoleucine--tRNA ligase, cytoplasmic Enzyme IC50 9.10 CHEMBL
Isoleucine--tRNA ligase Enzyme INHIBITOR DRUGBANK CHEMBL
Isoleucine--tRNA ligase Enzyme INHIBITOR CHEMBL CHEMBL
Isoleucine--tRNA ligase Enzyme Ki 8.60 CHEMBL
Isoleucine--tRNA ligase Enzyme Ki 7.22 CHEMBL
Isoleucine--tRNA ligase, putative, EC 6.1.1.5 Enzyme IC50 7.24 IUPHAR

External reference:

IDSource
4019345 VUID
N0000147519 NUI
D01076 KEGG_DRUG
115074-43-6 SECONDARY_CAS_RN
4019345 VANDF
4021018 VANDF
C0085259 UMLSCUI
CHEBI:7025 CHEBI
MRC PDB_CHEM_ID
CHEMBL719 ChEMBL_ID
CHEMBL3989715 ChEMBL_ID
D016712 MESH_DESCRIPTOR_UI
DB00410 DRUGBANK_ID
10916 IUPHAR_LIGAND_ID
5276 INN_ID
D0GX863OA5 UNII
446596 PUBCHEM_CID
221128 RXNORM
198973 MMSL
47751 MMSL
5138 MMSL
5139 MMSL
720 MMSL
002802 NDDF
005869 NDDF
387397004 SNOMEDCT_US
441528009 SNOMEDCT_US
71453003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 0093-1010 OINTMENT 20 mg TOPICAL ANDA 23 sections
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 0121-1076 OINTMENT 20 mg TOPICAL ANDA 24 sections
BACTROBAN HUMAN PRESCRIPTION DRUG LABEL 1 16590-028 CREAM 20 mg TOPICAL NDA 22 sections
MUPIROCIN HUMAN PRESCRIPTION DRUG LABEL 1 16590-158 OINTMENT 20 mg TOPICAL ANDA 16 sections
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 16714-055 CREAM 20 mg TOPICAL ANDA 28 sections
mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 17856-0112 OINTMENT 20 mg TOPICAL ANDA 20 sections
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 21695-188 OINTMENT 20 mg TOPICAL ANDA 19 sections
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 21922-029 CREAM 2 g TOPICAL ANDA 23 sections
MUPIROCIN HUMAN PRESCRIPTION DRUG LABEL 1 21922-073 OINTMENT 20 mg TOPICAL ANDA 24 sections
MUPIROCIN HUMAN PRESCRIPTION DRUG LABEL 1 21922-073 OINTMENT 20 mg TOPICAL ANDA 24 sections
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 42254-137 OINTMENT 20 mg TOPICAL ANDA 19 sections
mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 42254-229 OINTMENT 20 mg TOPICAL ANDA 20 sections
mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 45802-112 OINTMENT 20 mg TOPICAL ANDA 24 sections
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 45865-722 OINTMENT 20 mg TOPICAL ANDA 20 sections
MUPIROCIN HUMAN PRESCRIPTION DRUG LABEL 1 46708-624 CREAM 20 mg TOPICAL ANDA 22 sections
mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 50090-1587 OINTMENT 20 mg TOPICAL ANDA 24 sections
mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 50090-4349 OINTMENT 20 mg TOPICAL ANDA 24 sections
mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 50090-4397 OINTMENT 20 mg TOPICAL ANDA 24 sections
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 50268-568 OINTMENT 20 mg TOPICAL ANDA 25 sections
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 50436-0025 OINTMENT 20 mg TOPICAL ANDA 23 sections
mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 50436-0112 OINTMENT 20 mg TOPICAL ANDA 24 sections
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 50436-0180 OINTMENT 20 mg TOPICAL ANDA 22 sections
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 50436-1010 OINTMENT 20 mg TOPICAL ANDA 23 sections
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 51672-1312 OINTMENT 20 mg TOPICAL ANDA 25 sections
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 51672-1370 CREAM 20 mg TOPICAL ANDA 28 sections
mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 52959-743 OINTMENT 20 mg TOPICAL ANDA 20 sections
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 53002-9850 OINTMENT 20 mg TOPICAL ANDA 22 sections
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 53002-9851 OINTMENT 20 mg TOPICAL ANDA 24 sections
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 53002-9852 OINTMENT 20 mg TOPICAL ANDA 23 sections
mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 53002-9853 OINTMENT 20 mg TOPICAL ANDA 24 sections